REG - C4X Discovery - Business Update

C4X Discovery HoldingsAnnouncement

02/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220802:nRSB5163Ua&default-theme=true

RNS Number : 5163U  C4X Discovery Holdings PLC  02 August 2022

C4X Discovery Holdings plc

 

Business Update

 

Revenue generating progress for partnered programmes with continued momentum
across

drug discovery portfolio

 

2 August 2022 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, today provides a business update on the continued
progression across its Drug Discovery portfolio:

 

·    In July, C4XD received its first milestone payment of €3 million
from Sanofi under the out-licensing agreement for its IL-17A inhibitor
programme entered into in April 2021. Under the terms of the deal, C4XD is
entitled to receive up to a total of €414 million in upfront, pre-clinical,
development, regulatory and commercialisation milestone payments plus
royalties on future net sales.

·    Indivior has completed preparations for its Phase 1 multiple
ascending dose (MAD) study with C4X_3256 (INDV-2000), C4XD's oral Orexin-1
receptor antagonist for the treatment of addiction. The study is expected to
start in September 2022.

·    C4XD is in advanced stage commercial discussions for its NRF2
activator programme for inflammatory diseases with a deal anticipated in H2
2022.

·    MALT-1 inhibitor programme for haematological and solid tumours has
compounds that match the leading clinical candidate in terms of in vitro and
in vivo profile and is now moving towards identifying a Best-In-Class
shortlist of compounds.

·    a4b7 integrin programme has compounds in the lead series
significantly more potent in a human whole blood assay than representative
compounds from the leading clinical programme. Optimisation of pharmacokinetic
and pharmacodynamic profiles continues.

·    Six early-stage programmes (three oncology, three
inflammation-immunology) are appropriately resourced in the Hit Identification
phase, with a view to transitioning two into the next phase within the next
quarter.

·    Cathy Tralau-Stewart has stepped down by mutual consent from her
position as Chief Scientific Officer to pursue other interests. We thank Cathy
for her contribution while at C4XD and wish her well in her future endeavours.
Our existing and planned programmes continue to progress well under the
leadership of our SVPs Drug Discovery, Drs. Clare Murray and Nick Ray.

·    In Q1 2022, C4XD initiated a collaboration with Acellera to apply
insights from Acellera's machine learning and molecular simulation platforms
to an oncology programme in C4XD's portfolio. C4XD continues to evaluate
additional technology platforms, including AI and machine learning platforms,
with the potential to enhance its Drug Discovery engine and accelerate
programmes to a partnerable stage.

 

Dr Clive Dix, CEO of C4XD, said: "Our partnered portfolio has continued to
deliver over the past few months, most notably with our first milestone
payment from Sanofi for our oral IL-17a inhibitor to treat inflammatory
diseases. This was an important further step in demonstrating the commercial
value of C4XD's expertise, approach to drug discovery, and its business model.
Looking ahead, with partnering discussions advancing for our third programme,
NRF2, we remain well positioned for growth as multiple partnerable assets in
the pipeline continue strong progression."

 

 

- Ends -

 

 

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

 

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world leading medicines, which are developed by our
partners for the benefit of patients. We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced DNA-based
target identification and candidate molecule design capabilities, generating
small molecule drug candidates across multiple disease areas including
inflammation, oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early-stage novel target
opportunities to late-stage Drug Discovery programmes ready for out-licensing
to partners and we have two commercially partnered programmes with one
candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to
enrich our expertise and take our assets through pre-clinical and clinical
development. Through early-stage revenue-generating licensing deals, we
realise returns from our high value pre-clinical assets which are reinvested
to maximise the value of our Drug Discovery portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDEAKPFEEAAEFA